• FDA Raises Concerns About China-Developed Drugs FirstWordPharma
    February 10, 2022
    A negative FDA staff report for Eli Lilly and partner Innovent Biologics' anti-PD-1 cancer drug sintilimab could slow the plans of large Western drugmakers such as Novartis looking to sell Chinese-tested medicines...
PharmaSources Customer Service